MAASTRICHT, Netherlands — Mydrane, the first commercially launched intracameral mydriatic and anesthetic combination, proved effective and reliable in a study presented at the European Society of Cataract and Refractive Surgeons winter meeting.
Mydrane (Laboratoires Théa) is prepared into single-use vials containing a combination of 0.02% tropicamide, 0.31% phenylephrine and 1% lidocaine, and it comes in boxes of 20 vials.
An ongoing prospective study at University Hospital Ayr, Scotland, evaluated 142 eyes of 142 patients undergoing cataract surgery by a single surgeon. Patients received topical anesthesia, and no preoperative dilating drops or topical NSAIDs were used.
“The pupil dilates well and fast,” Rachel Haughney, MD, said. “Mean intraoperative time for pupil dilation was 27 seconds, ranging between 8 and 44 seconds. Time of surgery was 14.4 minutes, ranging from 10 to 30 minutes.”
Pupil size after Mydrane was 5 mm or more in 99% of patients, and the mean size was 6.5 mm.
“After injection of OVD, we measured pupil size again. A size of 6 mm was achieved in 100% of the patients, and the mean size was 7.5 mm. At the end of surgery, 99% of patients had maintained the same dilation. No patient in the cohort required any additional method or devices to maintain intraoperative mydriasis,” Haughney said. – by Michela Cimberle
Haughney R, et al. Efficacy and safety of the first commercially available intracameral mydriatic and anaesthetic during cataract surgery. European Society of Cataract and Refractive Surgeons winter meeting; Feb. 10-12, 2017; Maastricht, Netherlands.
Disclosure: Haughney reports no relevant financial disclosures.